The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vacchio, M. S.
Right arrow Articles by Ashwell, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vacchio, M. S.
Right arrow Articles by Ashwell, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METYRAPONE
Medline Plus Health Information
*Steroids
The Journal of Immunology, 1999, 163: 1327-1333.
Copyright © 1999 by The American Association of Immunologists

Thymus-Derived Glucocorticoids Set the Thresholds for Thymocyte Selection by Inhibiting TCR-Mediated Thymocyte Activation

Melanie S. Vacchio*, Jan Y. M. Lee* and Jonathan D. Ashwell1,{dagger}

* Experimental Immunology Branch and {dagger} Laboratory of Immune Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Selection processes in the thymus eliminate nonfunctional or harmful T cells and allow the survival of those cells with the potential to recognize Ag in association with self-MHC-encoded molecules (Ag/MHC). We have previously demonstrated that thymus-derived glucocorticoids antagonize TCR-mediated deletion, suggesting a role for endogenous thymic glucocorticoids in promoting survival of thymocytes following TCR engagement. Consistent with this hypothesis, we now show that inhibition of thymus glucocorticoid biosynthesis causes an increase in thymocyte apoptosis and a decrease in recovery that are directly proportional to the number of MHC-encoded molecules present and, therefore, the number of ligands available for TCR recognition. Expression of CD5 on CD4+CD8+ thymocytes, an indicator of TCR-mediated activation, increased in a TCR- and MHC-dependent manner when corticosteroid production or responsiveness was decreased. These results indicate that thymus-derived glucocorticoids determine where the window of thymocyte selection occurs in the TCR avidity spectrum by dampening the biological consequences of TCR occupancy and reveal that glucocorticoids mask the high percentage of self-Ag/MHC-reactive thymocytes that exist in the preselection repertoire.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Selection processes in the thymus eliminate nonfunctional or harmful T cells and allow the survival of those T cells with the potential to recognize Ag in association with self-MHC-encoded molecules (Ag/MHC).2 Thymocytes that express TCRs with high avidity for Ag/MHC undergo apoptosis (negative selection), while thymocytes that have not successfully rearranged their TCR genes or that express a receptor with subthreshold avidity for self Ag/MHC enter a default apoptosis pathway (death by neglect) (1, 2). Thymocytes bearing TCRs with moderate avidity for self Ag/MHC are rescued from the default death pathway and differentiate into mature T cells (positive selection). The molecular mechanism underlying the rescue of cells with moderate avidity and the death of cells with high avidity for self Ag/MHC is not known.

We have previously shown that the thymic epithelium produces steroids and have identified a role for endogenously produced glucocorticoids in thymocyte development. Analysis of transgenic mice that express antisense transcripts to the 3'-untranslated region of the glucocorticoid receptor (GR) in thymocytes, and which therefore have reduced GR levels and are hyporesponsive to glucocorticoids, revealed that glucocorticoids are critical at least two points during thymocyte development: progression from the CD4-CD8- to the CD4+CD8+ stage of development and maintenance of viability at the CD4+CD8+ stage (3). Moreover, addition of metyrapone, a selective inhibitor of corticosterone synthesis (4), to thymic organ culture of TCR {alpha}{beta} transgenic mice resulted in the specific apoptotic death of cells that would otherwise undergo positive selection (5, 6). These findings indicate that under normal conditions endogenous glucocorticoids prevent thymocyte apoptosis when the TCR binds self Ag/MHC with sufficient avidity to result in positive selection. Importantly, inhibition of glucocorticoid synthesis did not cause a decrease in cell recovery from thymi expressing nonselecting MHC-encoded molecules, demonstrating that TCR occupancy is necessary for cell death under these conditions.

In this report we have assessed the role of glucocorticoids in thymocyte development in nontransgenic mice. Unexpectedly, inhibition of glucocorticoid biosynthesis caused an increase in thymocyte apoptosis, a decrease in cell recovery, and an increase in cell surface markers of activation that was {alpha}{beta} TCR-dependent and directly proportional to the number of MHC-encoded molecules present. Moreover, in the absence of TCR ligands, inhibition of corticosteroid production actually enhanced thymocyte survival. These results demonstrate that the fraction of thymocytes that recognize self Ag/MHC with biologically significant avidity is large and form the basis of a model in which glucocorticoids inhibit activation (and therefore both positive and negative selection) of thymocytes in vivo.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mice and reagents

C57BL/6 (B6), C57BL/10 (B10), B10.BR, and B10.D2 mice were obtained from the Developmental Therapeutics Program, National Cancer Institute (Frederick, MD), and were used to generate timed pregnant animals. Males were removed from females after 16 h, and the day of separation was counted as day 0 of gestation. Mice in which {beta}2m expression has been eliminated by homologous recombination ({beta}2m-/-) were bred in our facility and had been backcrossed to C57BL/6 for at least six generations (7). C57BL/6 TCR{alpha}tm1Mom mice (B6.TCR{alpha}-/-) (8) were obtained from The Jackson Laboratory (Bar Harbor, ME). Fetal thymic organ cultures (FTOC) were performed in serum-free Nutridoma-SP medium (Boehringer Mannheim, Indianapolis, IN) supplemented with 20 mM HEPES, 100 µM nonessential amino acids, 1 mM sodium pyruvate, and 50 µM 2-ME. Metyrapone was purchased from ICN Biochemicals (Costa Mesa, CA). The Abs Y3P (anti-I-Ab) (9) and MKD6 (anti-I-Ad) (10) were purified by affinity chromatography. Abs used for flow cytometry, anti-CD4, anti-CD8, anti-TCR, anti-MHC, anti-CD5, and anti-CD69, were purchased from PharMingen (San Diego, CA).

Fetal thymic organ cultures

FTOC were performed as described (5). Fetal day 17 thymi were separated into lobes and cultured with 200–225 µg/ml of freshly diluted metyrapone or ethanol as a control on a Millipore filter (Bedford, MA) floating on a Gelfoam sponge in complete serum-free Nutridoma-SP medium (Boehringer Mannheim). Metyrapone, a selective inhibitor of the enzyme P450c11, blocks the conversion of biologically inactive deoxycorticosterone to the active form, corticosterone (4). In some experiments 10-9 M corticosterone, diluted in ethanol, was added. Cultures were conducted in either 1.5 ml of medium/well in 12-well plates or 3 ml of medium in six-well plates. Abs, 30 µg of Y3P (anti-I-Ab) or MKD6 (anti-I-Ad), or PBS as a control were added to cultures by dropping directly onto the thymi. Lobes were harvested after either 24 h (for TUNEL assay) or 3 days of culture, and single cell suspensions were prepared for counting and analyzed for CD4, CD8, TCR, CD5, CD69, and MHC expression by flow cytometry.

TUNEL assay

A modified form of the TUNEL assay (11) was used to detect fragmented DNA in apoptotic thymocytes (3). Briefly, thymocytes were incubated with anti-CD4-Red 670- and anti-CD8-PE-labeled Abs before formaldehyde fixation and permeabilization with 0.1% Triton X-100/0.1% sodium citrate, then subjected to a modified in situ nick translation using fluorescein-dUTP (Boehringer Mannheim). Labeled cells were visualized by flow cytometry with a FACScan. To determine the amount of apoptosis in the double-positive (DP) population, thymocytes were gated for expression of both CD4 and CD8 and analyzed for dUTP-FITC incorporation. The percent specific apoptosis was calculated by the formula: Percent specific apoptosis = [(experimental apoptosis - spontaneous apoptosis)/(100 - spontaneous apoptosis)] x 100.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Inhibition of corticosteroid production in FTOC decreases T cell recovery

Blockade of glucocorticoid synthesis in FTOC of thymi from TCR {alpha}{beta} transgenic mice has been shown to result in the death of thymocytes that normally undergo positive selection (6). To assess the contribution of endogenously produced glucocorticoids to the survival of thymocytes with an unrestricted range of TCR Ag specificities, we performed FTOC with B10 fetal day 17 thymi, which consist largely of TCR {alpha}{beta}+ CD4+CD8+ DP thymocytes, cultured in medium alone or with metyrapone to inhibit corticosterone production. After 3 days the thymi were harvested, counted, and evaluated for expression of CD4 and CD8. Culture in medium alone resulted in the recovery of 74.7 ± 12 x 104 DP thymocytes/lobe, whereas 38.9 ± 6.0 x 104 DP thymocytes/lobe were recovered from thymi cultured in the presence of metyrapone (a 52% decrease; Fig. 1Go). The decrease in DP thymocytes was reflected in decreased numbers of mature CD4+ thymocytes that developed in these cultures (14.9 ± 2.8 x 104 vs 8.5 ± 0.7 x 104). The number of CD4-CD8- thymocytes was similar in the two groups (10.6 ± 2.5 x 104 vs 8.5 ± 1.5 x 104). As we have previously noted, replacement of corticosterone with physiologic levels (10-9 M) of free corticosterone largely reversed the effect of metyrapone (63.4 ± 9.7 x 104 DP thymocytes/lobe).



View larger version (13K):
[in this window]
[in a new window]
 
FIGURE 1. Blockade of glucocorticoid synthesis decreases recovery of DP thymocytes. Fetal day 17 thymi from B10 mice were separated into lobes and cultured for 3 days in medium alone (n = 5), with 200 µg/ml of freshly diluted metyrapone (n = 4) or metyrapone in the presence of 10-9 M corticosterone (n = 5).

 
Effect of inhibiting glucocorticoid production on thymocyte recovery depends on the number of MHC-encoded molecules expressed

If the decrease in cell recovery caused by the inhibition of endogenous glucocorticoid production was in fact due to TCR occupancy unopposed by glucocorticoid signaling, one would expect that cell loss under these conditions would be reduced by decreasing the number of available ligands (and thus TCR occupancy). It is possible to vary the number of MHC-encoded molecules available for Ag presentation by using C57BL H-2 congenic strains of mice. The level of MHC expression reflects gene copy number, and it has been shown that both MHC class I- and class II-mediated positive and negative selection are sensitive to MHC gene dosage (12, 13, 14, 15). MHC-congenic animals differ in the number of different MHC-encoded molecules they express and, therefore, in the quantity and array of potential TCR ligands. That is, as the number of MHC molecules increases, so will the concentration of a given Ag/MHC TCR ligand. Moreover, as the number of different MHC molecules increases, so will the number of unique Ag/MHC complexes. B10.D2 (H-2d) mice express the full complement of MHC-encoded molecules, with three class I gene products (K, D, and L) and two MHC class II gene products (I-A and I-E) (16). H-2k haplotype (B10.BR) mice do not express an L allele (17) and therefore have four distinct MHC molecules. B10 (H-2b) mice also do not express an L allele and in addition have a deletion in the 5' portion of the gene encoding the {alpha}-chain of the I-E molecule, so that the only MHC class II molecule they express is encoded by I-A (18). Therefore, the number of different MHC-encoded molecules expressed by these otherwise genetically identical animals varies from three (B10) to five (B10.D2). FTOC of day 17 thymi from these mice was performed in the absence or the presence of metyrapone. To compare the results from multiple independent experiments, the data are expressed as thymocyte recovery in the presence of metyrapone compared with that observed with B10 thymi, which were included in each experiment. There was indeed a hierarchy of DP thymocyte loss when corticosterone biosynthesis was inhibited; the relative effect was B10.D2 (H-2d; Ld+, I-E+) > B10.BR (H-2k; Ld-, I-E+) > B10 (H-2b; Ld-, I-E-; Fig. 2Go). To further restrict the diversity of TCR ligands, thymi were tested from H-2b mice in which the {beta}2m locus has been disrupted by homologous recombination ({beta}2m-/-) and which therefore do not express MHC class I molecules (7, 19). For these thymi, which express only a single MHC-encoded molecule (I-A), the decrease in cell recovery was substantially less than that observed with B10 thymi. Therefore, cell loss due to inhibition of glucocorticoid synthesis varies directly with the number of MHC-encoded molecules expressed.



View larger version (23K):
[in this window]
[in a new window]
 
FIGURE 2. Effect of MHC-encoded molecule diversity on DP thymocyte recovery in the absence of glucocorticoids. Fetal day 17 thymi from B10, B10.BR, B10.D2, and {beta}2m-/- mice that had been backcrossed to C57BL/10 for at least six generations were separated into lobes and cultured in pairs for 3 days with or without 225 µg/ml of metyrapone. The recovery of CD4+CD8+ thymocytes in the presence of metyrapone was calculated for {beta}2m-/- (n = 5–9/experiment), B10.BR (n = 2–9/experiment), and B10.D2 (n = 4–5/experiment) and then expressed relative to the recovery of B10 DP thymocytes (n = 4–9/experiment), given a value of 1, in that experiment. The mean recovery of B10 thymocytes from FTOC with metyrapone was 59.3% (±7.7%) that of recovery in medium alone.

 
Apoptosis caused by inhibiting glucocorticoid production is MHC dependent

To determine whether the decrease in cell recovery caused by inhibition of glucocorticoid synthesis was due to enhanced cell death, apoptosis of DP thymocytes in FTOC was determined. After 24 h of culture in the absence or the presence of metyrapone, thymi were harvested, and thymocyte apoptosis was determined by flow cytometry using a modified TUNEL assay to detect nicked or fragmented DNA (6). Culture in metyrapone reproducibly induced substantial apoptosis in B10.D2 thymi, while having only a small effect in {beta}2m-/- thymi (a representative experiment is shown in Fig. 3GoA). Specific apoptosis was determined by subtracting the percentage of TUNEL+ thymocytes in the medium control from that observed in cultures with metyrapone. On the average, specific apoptosis of DP thymocytes induced by metyrapone in the {beta}2m-/- thymi was 2.2% (±0.6%), whereas in B10 thymi it was 5.4% (±1.2%). Metyrapone-induced specific apoptosis of DP cells was even greater in B10.D2 thymi (13.3 ± 2.8%). Therefore, just as for cell recovery, induction of cell death by inhibition of glucocorticoid production varied in direct proportion to the number of different MHC-encoded molecules. To eliminate any possibility of TCR occupancy by conventional Ag/MHC ligands, day 17 fetal thymi from H-2b {beta}2m-/- mice were cultured with or without metyrapone in medium alone or in medium containing mAbs to I-Ab (expressed by B10 mice) or I-Ad (an irrelevant Ab control; Fig. 4Go). Culture for 3 days in metyrapone resulted in recovery of 76% of the cells compared with culture in medium alone. Addition of anti-I-Ad to metyrapone cultures had no effect (81% recovery). In contrast, when the only classic MHC-encoded molecule, I-Ab, was blocked with Ab, metyrapone caused no decrease in thymocyte recovery. In fact, there was a reproducible increase in thymocyte recovery (134% of medium alone). Therefore, in the absence of TCR ligands, prevention of glucocorticoid biosynthesis did not decrease and, in fact, enhanced, thymocyte survival.



View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 3. Effect of MHC-encoded molecule diversity on DP thymocyte apoptosis in the absence of glucocorticoids. Fetal day 17 thymi from B10, B10.D2, and {beta}2m-/- mice were separated into lobes and cultured in pairs for 24 h with or without 225 µg/ml of metyrapone, then analyzed for TUNEL positivity and CD4/CD8 expression. A, Representative profiles from B10.D2 and {beta}2m-/- thymi cultured in either medium or metyrapone, gated on CD4 and CD8 expression, then analyzed for incorporation of dUTP-FITC in the TUNEL assay. B, Specific apoptosis of DP thymocytes ({beta}2m-/-, n = 20; B10, n = 19; B10.D2, n = 26).

 


View larger version (16K):
[in this window]
[in a new window]
 
FIGURE 4. Blockade of glucocorticoid synthesis enhances thymocyte recovery in the absence of TCR ligands. Fetal day 17 thymi from H-2b {beta}2m-/- mice were cultured with 225 µg/ml metyrapone or an ethanol control for 3 days in medium alone (n = 30), 10 µg/ml Y3P (anti-I-Ab; n = 18), or 10 µg/ml of a control Ab, MKD6 (anti-I-Ad; n = 11). The recovery of CD4+CD8+ thymocytes was calculated for each treatment group, and the fractional change caused by culture with metyrapone is shown.

 
Removal of glucocorticoid effects reveals a large population of self-reactive thymocytes

Although the relationship between MHC expression and the effect of corticosteroid withdrawal on thymocyte survival indicated that glucocorticoids play an important role in the survival of cells recognizing self Ag/MHC, the actual number of cells affected by metyrapone was larger than would be predicted based upon the number of CD4+CD8+ cells that normally undergo positive selection (estimated to be 3–4%) (20). Rather, the observation that TCR engagement by self Ag/MHC appears to result in substantial apoptotic death and decreased cell recovery when glucocorticoid production is inhibited suggests that a large number (>=50%) of thymocytes express TCRs with biologically relevant avidity for self Ag/MHC. An independent means of testing this is to measure cell surface levels of CD5, a molecule whose expression is dependent upon TCR-mediated signaling and whose up-regulation on immature thymocytes is an early and sensitive marker of even low (nonselecting) avidity TCR/ligand interactions (21, 22). Two different methods were used to assess the effect of diminishing glucocorticoid signaling on DP thymocyte activation. First, thymi from {beta}2m-/- (one MHC molecule) and B10.A mice (five MHC molecules) were compared (Fig. 5GoA). As previously noted, CD5 levels increase on DP, but not on CD4+CD8-, thymocytes as a function of MHC expression, presumably reflecting low avidity TCR interactions (22). Fetal thymi from {beta}2m-/- and B10.A mice were cultured with or without metyrapone, and CD5 expression was determined 18 h later (Fig. 5GoB). The low level of CD5 expression on {beta}2-/- DP thymocytes did not appreciably change in the presence of metyrapone, indicating that inhibiting glucocorticoid production has little effect on CD5 expression when there is minimal TCR occupancy. In contrast, CD5 levels on B10.A DP thymocytes increased ~40% in the presence of metyrapone (CD5 mean fluorescence intensities were 1037 ± 118 in medium (n = 12) and 1448 ± 105 with metyrapone (n = 6)). In other experiments, up-regulation of CD5 on DP thymocytes was found as early as 8 h after adding metyrapone, a time at which there was no detectable apoptosis, demonstrating that the increase in CD5 expression was not the result of selective survival of a thymocyte subpopulation (data not shown). To determine whether the increase in CD5 expression did indeed depend upon TCR occupancy, a comparison was made between cells from B6 thymi and those from thymi from B6 mice lacking TCR{alpha} (B6.TCR{alpha}-/-). Thymocytes from these animals express a pre-TCR, which allows them to progress to the DP stage of development, but do not undergo selection because they lack an {alpha}{beta} TCR (8). Treatment of TCR{alpha}-/- thymi with metyrapone for 24 h had no effect on DP thymocyte CD5 expression (Fig. 5GoC). In contrast, metyrapone reproducibly increased the levels of CD5 on DP thymocytes from TCR{alpha}-expressing mice, demonstrating that a TCR capable of recognizing Ag/MHC must be present for a decrease in glucocorticoids to cause thymocyte activation. For an independent approach to this issue, DP thymocytes from transgenic mice expressing antisense GR transcripts, and thus hyporesponsive to glucocorticoids (3), were analyzed for CD5 expression (Fig. 6Go). As with inhibition of glucocorticoid synthesis, expression of the GR antisense transgene resulted in up-regulation of CD5 expression on CD4+CD8+ thymocytes. It is interesting that the CD5 level on all DP thymocytes increased when glucocorticoid synthesis or responsiveness was inhibited, suggesting that TCRs on all thymocytes may have at least some degree of biologically significant avidity for any MHC-encoded molecule regardless of the specific peptide Ag it binds. Together, these results demonstrate that reduction in endogenous glucocorticoid production or responsiveness to glucocorticoids leads to an increase in TCR-mediated activation of DP cells by endogenous Ag/MHC.



View larger version (30K):
[in this window]
[in a new window]
 
FIGURE 5. Inhibition of glucocorticoid synthesis results in enhanced CD5 expression on DP thymocytes. A, Flow cytometric analysis of CD5 expression on DP (gate R1) and CD4+CD8- (gate R2) thymocytes from 3- to 6-wk-old {beta}2m-/- and B10.A mice. One representative experiment of five is shown. B, Fetal day 17 thymi from B10.A and {beta}2m-/- mice were cultured for 24 h with or without 225 µg/ml of metyrapone, then analyzed for CD5, CD8, and TUNEL positivity. Representative profiles from B10.A and {beta}2m-/- thymi cultured in either medium or metyrapone, gated on CD8+ TUNEL- cells, were analyzed for CD5 expression. C, Fetal day 17 thymi from B6 (medium, n = 4; metyrapone, n = 5) or B6.TCR{alpha}-/- (medium, n = 3; metyrapone, n = 4) mice were cultured for 24 h with or without metyrapone and analyzed for CD5 expression as in B. Profiles representative of the average mean fluorescence intensity for each group are shown.

 


View larger version (41K):
[in this window]
[in a new window]
 
FIGURE 6. CD5 expression is increased on DP thymocytes that are hyporesponsive to glucocorticoids. Representative profiles in which thymi from 3- to 6-wk-old B6 and B6.TKO mice were analyzed for CD4, CD8, and CD5 expression. CD5 profiles of DP thymocytes (R1 gate, upper panels) are shown in the lower panel.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The data in this report demonstrate that in the absence of thymus-derived glucocorticoids there is a direct relationship between deletion of DP thymocytes and the number of different MHC-encoded molecules expressed. A particularly interesting observation is that under conditions in which thymocytes could not encounter MHC/peptide ligands, inhibition of corticosteroid production actually increased thymocyte recovery. This suggests that locally produced corticosterone, just as corticosterone produced by the adrenals (23), causes immature thymocytes to die and implies that thymus-derived steroids participate in the death of thymocytes expressing receptors with very low avidity for self Ag/MHC. The magnitude of the effect of eliminating glucocorticoid production on thymocyte survival in the presence of MHC-encoded molecules raises another, quantitative, issue: how much of the preselection TCR repertoire is capable of binding self Ag/MHC with biologically relevant avidity? It was long thought that only a small number of thymocytes express TCRs with biologically relevant avidity for self Ag/MHC (that is, bear receptors capable of transducing activating signals). Quantitative analyses of thymocyte turnover suggest that only a small proportion of thymocytes (3–4%) survive these selection processes and leave the thymus (19, 24). Furthermore, examination of tissue sections for apoptotic cells revealed no obvious difference between thymi from mice that did and those that did not express MHC-encoded molecules (25). These results have been thought to indicate that only a small number of thymocytes express TCRs that recognize self Ag/MHC with sufficient avidity to trigger biological responses.

This issue has recently been revisited by a number of groups using different experimental approaches, and the consensus is that a sizable fraction of the preselection TCR repertoire is, in fact, capable of recognizing Ag/MHC. For example, addition of a single peptide Ag to cultured thymi from TAP1-/- mice (which cannot themselves generate self peptides that bind to MHC class I molecules) caused the generation of a small, but measurable, population of CD4-CD8+ cells (26), as did the addition of {beta}2m and a single peptide to cultures of {beta}2m-/- thymi (27). In both cases, mixtures of peptides were more efficient than single peptides. Another approach that analyzed the anti-MHC class II repertoire was to generate transgenic mice that expressed only a single MHC class II molecule, I-Ab, covalently bound to an antigenic peptide (28). This resulted in positive selection of a relatively large number of CD4+ thymocytes. The peripheral CD4+ T cells in these animals had a diverse repertoire, as assessed by V{beta} expression, and a very high percentage of T cell hybridomas generated from these cells responded to I-Ab plus unknown self peptides or allogeneic MHC-encoded molecules. The authors concluded that the TCR repertoire is inherently biased toward MHC molecules, and that a relatively large number of thymocytes do, in fact, recognize self peptides/MHC with biologically significant avidity. They suggested that these cells are not apparent in normal animals after positive selection on a low to moderate avidity peptide/MHC combination because they are subsequently deleted on a cross-reactive, but higher avidity, ligand. T cell reactivity has also been studied in mice that lack the I-A {alpha}-chain and therefore express only an abnormal MHC class II molecule consisting of an I-A{beta} homodimer (29). The finding that T cells from these mice, which developed in the absence of MHC class II {alpha}{beta} heterodimers, nonetheless had a high frequency of cells that responded to normal allogeneic class II molecules was taken to mean that the germline TCR repertoire has been selected for MHC reactivity.

Several recent studies that attempted to directly analyze the preselection TCR repertoire. In one case, CD4+ T cell hybridomas were made from anti-TCR-stimulated thymi from MHC class I/II-negative mice (30). The frequency of MHC-reactive hybridomas was high, with 4.4% of the cells responding to a given MHC class II molecule, similar to the frequency of control hybridomas responding to allogeneic MHC. More than 30% of the cells responded to at least one of the eight MHC haplotypes tested. Based upon these results and the assumption that anti-MHC class I cells should arise with similar frequency, it was estimated that 20–30% of thymocytes in an outbred mouse might be autoreactive. In another study, the frequency of preselection thymocytes capable of responding to MHC was determined using a short term thymic reaggregate culture system (22). It was found that 24 h after exposure to MHC+ stroma, 15% of thymocytes expressed CD69. Using CD5 as a measure of activation, it was reported that 11% of cells responded to I-Ab, 10% responded to H-2Kb and Db, and 19% responded when both were present. Furthermore, while CD5 was not expressed on fresh DP thymocytes from mice lacking MHC molecules, over 20% of DP cells from mice expressing either MHC class I or I-Ab were positive for CD5, and it was mentioned that up to 50% were CD5+ in mice expressing the MHC class II I-E molecule.

The data in the present study indicate that glucocorticoids interfere with the activation of thymocytes with low, but biologically relevant, avidity for self Ag/MHC, as reflected in lowered levels of CD5. The up-regulation of CD5 by metyrapone did not occur in the absence of a mature TCR, indicating that signaling via CD4 or CD8 alone cannot account for this effect. However, the data do not rule out a supplementary role for signaling via these molecules, either independent of the TCR signal or, more likely, in their capacity as TCR coreceptors. Glucocorticoids are well known to potently antagonize activation of mature T cells and inhibit transcriptional activation of, among other gene products, cytokines such as IL-1, IL-2, IL-4, and IFN-{gamma} (31). There are a variety of distinct mechanisms by which glucocorticoids may mediate these effects (reviewed in Ref. 32). The occupied GR may bind to a response element in the regulatory region of a target gene and repress transcription. Alternatively, the GR may interfere, by direct or indirect physical interactions, with the activity of other transcription factors such as AP-1. It has also been found that glucocorticoids up-regulate the expression of I{kappa}B, sequestering NF-{kappa}B in the cytosol and decreasing its transcriptional activity (33, 34), although direct interactions between the GR and NF-{kappa}B p65 may also contribute to this inhibition (35, 36). Yet another mechanism for inhibitory cross-talk between the GR and a host of other transcription factors is competition for coactivators of gene transcription such as p300/CBP (37). Finally, it has been reported that glucocorticoids may inhibit some proximal events in TCR signaling, such as phosphatidylinositol turnover and Ca2+ flux (38).

The conventional model of thymocyte selection holds that the large majority of thymocytes die in the thymus because their TCRs fail to bind self Ags/MHC with biologically significant avidity (2). Only a small fraction of thymocytes bind self ligands with sufficient avidity to either be rescued from this default "neglect" death pathway or be induced to undergo activation-induced apoptosis. As detailed above, it is becoming clear that a substantial fraction of thymocytes do, in fact, recognize self Ag/MHC with sufficient avidity to receive activation signals, although only a small number actually traverse the entire process to become mature SP thymocytes. To accommodate this and our results with glucocorticoids, we suggest the following relationship between TCR avidity for self Ag/MHC and cell fate. In this model, as with the conventional model, thymocytes bearing TCRs with high avidity are negatively selected, those with intermediate avidity are positively selected. There is a large additional population of cells, however, with TCRs that recognize self Ag/MHC with low, but biologically significant, avidity (sufficient to cause up-regulation of CD5, for example). The activation of all thymocytes in all TCR avidity groups is inhibited by glucocorticoids. In the case of cells with intermediate avidity, this would prevent them from expressing whatever gene products would otherwise be induced to cause apoptosis (negative selection) and allow differentiation (positive selection) to proceed. For low avidity thymocytes, corticosteroids would prevent expression of gene products necessary for differentiation (positive selection). As glucocorticoid levels decrease, the biological consequences of receptor occupancy are enhanced, as reflected by increased expression of CD5 and CD69, so that thymocytes signaled via lower avidity interactions in the absence of glucocorticoids respond like thymocytes signaled via higher avidity interactions in the presence of glucocorticoids. As a result, thymocytes that would be positively selected in the presence of glucocorticoids become negatively selected in their absence, and cells with low avidity that would normally be inadequately activated, and thus be lost, would progress to the SP stage of development. In vivo, the ultimate consequence of this would be the selection of T cells whose receptors would, on the average, have lower avidity for self Ag/MHC than the normally selected repertoire.

This model is consistent with a variety of observations. Inhibition of glucocorticoid production in FTOC makes DP thymocytes exquisitely sensitive to anti-TCR-mediated deletion (5). In a more physiological setting, lack of thymus-derived corticosteroids results in the TCR-mediated deletion of cells that are otherwise positively selected because they recognize self Ag/MHC with intermediate avidity (6). Finally, reduction in thymocyte GR levels, which renders them hyporesponsive to glucocorticoids, results in loss of MHC-dependent positive selection of T cells bearing particular V{beta}s and markedly reduces the autoimmunity and lymphoproliferative disease of MRL-lpr/lpr mice (39). Thus, the effect of glucocorticoids on thymocyte development can be viewed as analogous to their effect on peripheral T cells. They act as immunosuppressants by preventing expression of activation-induced genes. In the case of peripheral T cells, this activity results in inhibition of effector function. In the case of thymocytes, this activity determines what range of TCR avidities for self Ag/MHC will fall in the positive selection window (i.e., affects development). It is an interesting speculation that thymic production of corticosteroids may have evolved to ensure that T cells surviving selection have sufficient avidity for self MHC to respond to Ags even in the face of stress-induced glucocorticoid levels, such as occur during acute illness.


    Acknowledgments
 
We thank Drs. Ronald Schwartz and Susan Epstein for providing {beta}2m-/- mice, Jeff Bluestone for helpful discussions, and Allan Weissman, Ronald Schwartz, Ronald Germain, and Richard Hodes for critical review of the manuscript.


    Footnotes
 
1 Address correspondence and reprint requests to Dr. Jonathan Ashwell, Room 1B-40, Building 10, National Institutes of Health, Bethesda, MD 20892. E-mail address: Back

2 Abbreviations used in this paper: Ag/MHC, Ag in association with self-MHC-encoded molecules; GR, glucocorticoid receptor; FTOC, fetal thymic organ culture; DP, double positive. Back

Received for publication February 9, 1999. Accepted for publication May 24, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Sprent, J., D. Lo, E.-K. Gao, Y. Ron. 1988. T cell selection in the thymus. Immunol. Rev. 101:172.
  2. Schwartz, R. H.. 1989. Acquisition of immunologic self-tolerance. Cell 57:1073.[Medline]
  3. King, L. B., M. S. Vacchio, K. Dixon, R. Hunziker, D. H. Margulies, J. D. Ashwell. 1995. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity 3:647.[Medline]
  4. Jr Haynes, R. C.. 1990. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. eds. The Pharmacological Basis of Therapeutics 1431. Pergamon Press, New York.
  5. Vacchio, M. S., V. Papadopoulos, J. D. Ashwell. 1994. Steroid production in the thymus: implications for thymocyte selection. J. Exp. Med. 179:1835.[Abstract/Free Full Text]
  6. Vacchio, M. S., J. D. Ashwell. 1997. Thymus-derived glucocorticoids regulate antigen-specific positive selection. J. Exp. Med. 185:2033.[Abstract/Free Full Text]
  7. Ziljstra, M., M. Bix, N. E. Simister, J. M. Loring, D. H. Raulet, R. Jaenisch. 1990. {beta}2-Microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 344:742.[Medline]
  8. Mombaerts, P., A. R. Clarke, M. A. Rudnicki, J. Iacomini, S. Itohara, J. J. Lafaille, L. Wang, Y. Ichikawa, R. Jaenisch, M. L. Hooper, et al 1992. Mutations in T-cell antigen receptor genes {alpha} and {beta} block thymocyte development at different stages. Nature 360:225.[Medline]
  9. Jr Janeway, C. A., P. J. Conrad, E. A. Lerner, J. Babich, P. Wettstein, D. B. Murphy. 1984. Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: possible role of T cell bound Ia antigen as targets of immunoregulatory T cells. J. Immunol. 132:662.[Abstract]
  10. Kappler, J. W., B. Skidmore, J. White, P. Marrack. 1981. Antigen-inducible, H-2 restricted, interleukin-2-producing T cell hybridomas: lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1198.[Abstract/Free Full Text]
  11. Gavrieli, Y., Y. Sherman, S. A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493.[Abstract/Free Full Text]
  12. Kisielow, P., H. S. Teh, H. Blüthmann, H. von Boehmer. 1988. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 335:730.[Medline]
  13. Berg, L. J., G. D. Frank, M. M. Davis. 1990. The effects of MHC gene dosage and allelic variation on T cell receptor selection. Cell 60:1043.[Medline]
  14. Spain, L. M., L. J. Berg. 1994. Quantitative analysis of the efficiency of clonal deletion in the thymus. Dev. Immunol. 4:43.[Medline]
  15. Hemendinger, R. A., M. M. Miller, S. E. Bloom. 1995. Selective expression of major histocompatibility complex (MHC) antigens and modulation of T-cell differentiation in chickens with increased MHC-chromosome dosages. Vet. Immunol. Immunopathol. 46:303.[Medline]
  16. Shreffler, D., C. David, D. Gotze, J. Klein, H. McDevitt, D. Sachs. 1974. Genetic nomenclature for new lymphocyte antigens controlled by the Ir region of the H-2 complex. Immunogenetics 1:189.
  17. Tummuru, U., M. K. Zubairu, D. R. Lee. 1992. The multi-locus H-2Dw16 region has an organization distinct from the Dd region. Immunogenetics 35:296.[Medline]
  18. Mathis, D. J., C. Benoist, V. E. Williams, N. Kanter, H. D. McDevitt. 1983. Several mechanisms can account for defective E{alpha} gene expression in different mouse haplotypes. Proc. Natl. Acad. Sci. USA 80:273.[Abstract/Free Full Text]
  19. Koller, B. H., P. Marrack, J. W. Kappler. 1990. Normal development of mice deficient in {beta}2M, MHC class I proteins and CD8+ T cells. Science 248:1227.[Abstract/Free Full Text]
  20. Shortman, K., M. Egerton, G. J. Spangrude, R. Scollay. 1990. The generation and fate of thymocytes. Semin. Immunol. 2:3.[Medline]
  21. Dutz, J. P., C. J. Ong, J. Marth, H. S. Teh. 1995. Distinct differentiative stages of CD4+ CD8+ thymocyte development defined by the lack of coreceptor binding in positive selection. J. Immunol. 154:2588.[Abstract]
  22. Merkenschlager, M., D. Graf, M. Lovatt, U. Bommhardt, R. Zamoyska, A. G. Fisher. 1997. How many thymocytes audition for selection?. J. Exp. Med. 186:1149.[Abstract/Free Full Text]
  23. Dougherty, T. F.. 1952. Effect of hormones on lymphatic tissue. Physiol. Rev. 32:379.[Free Full Text]
  24. Shortman, K., D. Vremec, M. Egerton. 1991. The kinetics of T cell antigen receptor expression by subgroups of CD4+8+ thymocytes: delineation of CD4+8+3(2+) thymocytes as post-selection intermediates leading to mature T cells. J. Exp. Med. 173:323.[Abstract/Free Full Text]
  25. Surh, C. D., J. Sprent. 1994. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100.[Medline]
  26. Ashton-Rickardt, P. G., L. Van Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa. 1993. Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell 73:1041.[Medline]
  27. Hogquist, K. A., M. A. Gavin, M. J. Bevan. 1993. Positive selection of CD8+ T cells induced by major histocompatibility complex binding peptides in fetal thymic organ culture. J. Exp. Med. 177:1469.[Abstract/Free Full Text]
  28. Ignatowicz, L., J. Kappler, P. Marrack. 1996. The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84:521.[Medline]
  29. Vidovic, D., N. Boulanger, O. Kuye, J. Toral, K. Ito, J. Guenot, H. Bluethmann, Z. A. Nagy. 1997. The helper T-cell repertoire of mice expressing class II major histocompatibility complex {beta} chains in the absence of {alpha} chains. Immunogenetics 45:325.[Medline]
  30. Zerrahn, J., W. Held, D. H. Raulet. 1997. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88:627.[Medline]
  31. Almawi, W. Y., H. N. Beyhum, A. A. Rahme, M. J. Rieder. 1996. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukocyte Biol. 60:563.[Abstract]
  32. Zacharchuk, C. M., J. D. Ashwell. 1992. Fruitful outcomes of intracellular cross-talk. Curr. Biol. 2:246.[Medline]
  33. Scheinman, R. I., P. C. Cogswell, A. K. Lofquist, Jr A. S. Baldwin. 1995. Role of transcriptional activation of I{kappa}B{alpha} in mediation of immunosuppression by glucocorticoids. Science 270:283.[Abstract/Free Full Text]
  34. Auphan, N., J. A. Didonata, C. Rosette, A. Hemberg, M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-{kappa}B activity through induction of I{kappa}B synthesis. Science 270:286.[Abstract/Free Full Text]
  35. Ray, A., K. E. Prefontaine. 1994. Physical association and functional antagonism between the p65 subunit of transcription factor NF-{kappa}B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 91:752.[Abstract/Free Full Text]
  36. De Bosscher, K., M. L. Schmitz, W. Vanden Berghe, S. Plaisance, W. Fiers, G. Haegeman. 1997. Glucocorticoid-mediated repression of nuclear factor-{kappa}B-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. USA 94:13504.[Abstract/Free Full Text]
  37. Shibata, H., T. E. Spencer, S. A. Onate, G. Jenster, S. Y. Tsai, M. J. Tsai, B. W. O’Malley. 1997. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 52:141.
  38. Baus, E., F. Andris, P. M. Dubois, J. Urbain, O. Leo. 1996. Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. J. Immunol. 156:4555.[Abstract]
  39. Tolosa, E., L. B. King, J. D. Ashwell. 1998. Thymocyte glucocorticoid resistance alters positive selection and inhibits autoimmunity and lymphoproliferative disease in MRL-lpr/lpr mice. Immunity 8:67.[Medline]



This article has been cited by other articles:


Home page
EndocrinologyHome page
C. E. Gomez-Sanchez
Glucocorticoid Production and Regulation in Thymus: Of Mice and Birds
Endocrinology, September 1, 2009; 150(9): 3977 - 3979.
[Full Text] [PDF]


Home page
EndocrinologyHome page
S. Qiao, S. Okret, and M. Jondal
Thymocyte-Synthesized Glucocorticoids Play a Role in Thymocyte Homeostasis and Are Down-Regulated by Adrenocorticotropic Hormone
Endocrinology, September 1, 2009; 150(9): 4163 - 4169.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
Z. Stojic-Vukanic, A. Rauski, D. Kosec, K. Radojevic, I. Pilipovic, and G. Leposavic
Dysregulation of T-Cell Development in Adrenal Glucocorticoid-Deprived Rats
Experimental Biology and Medicine, September 1, 2009; 234(9): 1067 - 1074.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. D'Elia, J. Patenaude, and J. Bernier
Regulation of glucocorticoid sensitivity in thymocytes from burn-injured mice
Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E97 - E104.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. Kuwano, C. M. Prazma, N. Yazawa, R. Watanabe, N. Ishiura, A. Kumanogoh, H. Okochi, K. Tamaki, M. Fujimoto, and T. F. Tedder
CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells
Int. Immunol., August 1, 2007; 19(8): 977 - 992.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. J. Cole, D. R. Liddicoat, and D. I. Godfrey
Intrathymic Glucocorticoid Production and Thymocyte Survival: Another Piece in the Puzzle
Endocrinology, June 1, 2005; 146(6): 2499 - 2500.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. D'Elia, J. Patenaude, C. Hamelin, D. R. Garrel, and J. Bernier
Corticosterone binding globulin regulation and thymus changes after thermal injury in mice
Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E852 - E860.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Y. Zhang, X. Ding, and R. A. Daynes
The Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type I by Lymphocytes Provides a Novel Means for Intracrine Regulation of Glucocorticoid Activities
J. Immunol., January 15, 2005; 174(2): 879 - 889.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
I. Cima, N. Corazza, B. Dick, A. Fuhrer, S. Herren, S. Jakob, E. Ayuni, C. Mueller, and T. Brunner
Intestinal Epithelial Cells Synthesize Glucocorticoids and Regulate T Cell Activation
J. Exp. Med., December 20, 2004; 200(12): 1635 - 1646.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. Zhan, D. P. Funda, A. L. Every, P. Fundova, J. F. Purton, D. R. Liddicoat, T. J. Cole, D. I. Godfrey, J. L. Brady, S. I. Mannering, et al.
TCR-mediated activation promotes GITR upregulation in T cells and resistance to glucocorticoid-induced death
Int. Immunol., September 1, 2004; 16(9): 1315 - 1321.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Ko, J. Jang, J. Ahn, K. Lee, H. Chung, S. H. Jeon, and R. H. Seong
T Cell Receptor Signaling Inhibits Glucocorticoid-induced Apoptosis by Repressing the SRG3 Expression via Ras Activation
J. Biol. Chem., May 21, 2004; 279(21): 21903 - 21915.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. P. Hale and M. L. Markert
Corticosteroids Regulate Epithelial Cell Differentiation and Hassall Body Formation in the Human Thymus
J. Immunol., January 1, 2004; 172(1): 617 - 624.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M.-L. Bergman, N. Duarte, S. Campino, M. Lundholm, V. Motta, K. Lejon, C. Penha-Goncalves, and D. Holmberg
Diabetes Protection and Restoration of Thymocyte Apoptosis in NOD Idd6 Congenic Strains
Diabetes, July 1, 2003; 52(7): 1677 - 1682.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
G. L. Stephens, J. D. Ashwell, and L. Ignatowicz
Mutually antagonistic signals regulate selection of the T cell repertoire
Int. Immunol., May 1, 2003; 15(5): 623 - 632.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Brewer, B. P. Sleckman, W. Swat, and L. J. Muglia
Green Fluorescent Protein-Glucocorticoid Receptor Knockin Mice Reveal Dynamic Receptor Modulation During Thymocyte Development
J. Immunol., August 1, 2002; 169(3): 1309 - 1318.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
T. Berki, L. Palinkas, F. Boldizsar, and P. Nemeth
Glucocorticoid (GC) sensitivity and GC receptor expression differ in thymocyte subpopulations
Int. Immunol., May 1, 2002; 14(5): 463 - 469.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
O. Lechner, H. Dietrich, G. J. Wiegers, M. Vacchio, and G. Wick
Glucocorticoid production in the chicken bursa and thymus
Int. Immunol., June 1, 2001; 13(6): 769 - 776.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Van Laethem, E. Baus, L. A. Smyth, F. Andris, F. Bex, J. Urbain, D. Kioussis, and O. Leo
Glucocorticoids Attenuate T Cell Receptor Signaling
J. Exp. Med., April 2, 2001; 193(7): 803 - 814.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. F. Torres-Roca, J. W. Tung, D. R. Greenwald, J. M. Brown, L. A. Herzenberg, L. A. Herzenberg, and P. D. Katsikis
An Early Oxygen-Dependent Step Is Required for Dexamethasone-Induced Apoptosis of Immature Mouse Thymocytes
J. Immunol., November 1, 2000; 165(9): 4822 - 4830.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Livak, D. B. Burtrum, L. Rowen, D. G. Schatz, and H. T. Petrie
Genetic Modulation of T Cell Receptor Gene Segment Usage during Somatic Recombination
J. Exp. Med., October 16, 2000; 192(8): 1191 - 1196.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Zhang, K. Mikecz, A. Finnegan, and T. T. Glant
Spontaneous Thymocyte Apoptosis Is Regulated by a Mitochondrion-Mediated Signaling Pathway
J. Immunol., September 15, 2000; 165(6): 2970 - 2974.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
W. Savino and M. Dardenne
Neuroendocrine Control of Thymus Physiology
Endocr. Rev., August 1, 2000; 21(4): 412 - 443.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
U. Bommhardt, Y. Scheuring, C. Bickel, R. Zamoyska, and T. Hunig
MEK Activity Regulates Negative Selection of Immature CD4+CD8+ Thymocytes
J. Immunol., March 1, 2000; 164(5): 2326 - 2337.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vacchio, M. S.
Right arrow Articles by Ashwell, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vacchio, M. S.
Right arrow Articles by Ashwell, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METYRAPONE
Medline Plus Health Information
*Steroids


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS